All companies
Quest Diagnostics logo

What smart money is saying about Quest DiagnosticsUnited States flag

DGX · Healthcare · Medical - Diagnostics & Research · Market cap $25.99B

1 fund in our archive has pitched Quest Diagnostics — most recently Tributary Capital Management All Cap Plus Equity Strategy in June 2026.

Company profile

Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.

Get an email when a fund writes about it

Summarize with Warren AI
2
Reported positions
2
Bought
0
Sold
2
Letters

Position history

Every position in Quest Diagnostics on record in the archive was reported in Q2 2026, across 2 fund letters2 opened or added to the position.

Fund letters reporting a position in Quest Diagnostics, by quarter
QuarterLettersBoughtSoldTheses
Q2 20262201

Fund activity · 2 positions · 2 moves

  • New positionTributary Capital Management All Cap Equity Strategy
    June 2026
    There were two initiations and three eliminations in the All Cap portfolio during the second quarter. Quest Diagnostics was initiated as a new position. The company is a leading provider of clinical laboratory testing and associated services.
    Read the letterQuest Diagnostics
  • New positionTributary Capital Management All Cap Plus Equity Strategy
    June 2026
    There were two initiations and three eliminations in the All Cap Plus portfolio during the second quarter. Quest Diagnostics was initiated as a new position. The company is a leading provider of clinical laboratory testing and associated services.
    Read the letterQuest Diagnostics

Fund coverage · 1 thesis

  • Tributary Capital Management All Cap Plus Equity Strategy
    June 2026

    Quest Diagnostics is a leading clinical laboratory testing provider with a broad national network and industry-leading test menu.

    Read the full thesis

Read every full thesis on Quest Diagnostics

Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.

View plans
Share this ledger